In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 and BioCryst Pharmaceuticals, Inc. (BCRX) 10-day simple moving average is 7.67. BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioCryst Pharmaceuticals projects 2025 ORLADEYO net revenue of $515-$535 million and total revenue of $540-$560 million. BioCryst Pharmaceuticals announced its preliminary unaudited ORLADEYO ...

ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 ...

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ® (berotralstat) net revenue and total revenue for the fourth quarter and full year 2024. The company ...